0000109657 false 0000109657 2021-09-17 2021-09-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report:

(Date of earliest event reported)

September 17, 2021

GT Biopharma, Inc.
(Exact name of registrant as specified in its charter)

Delaware

(State or other Jurisdiction of Incorporation)

1-40023 |  | 94-1620407
(Commission File Number) |  | (IRS Employer Identification No.)

9350 Wilshire Blvd., Suite 203 Beverly Hills, CA 90212 (Address of Principal Executive Offices and zip code)

(800) 304-9888

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class |  | Trading Symbol(s) |  | Name of each Exchange on which registered
Common stock, $0.001 par value |  | GTBP |  | The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On September 17, 2021, Dr. Jeffrey Miller, a Professor of Medicine, University of Minnesota Medical School, Division of Hematology, Oncology and Transplantation and the Registrant’s consulting Chief Scientific Officer, presented information regarding the Registrant’s drug candidates at the European Society for Medical Oncology Congress 2021. Dr. Miller’s presentation is filed as Exhibit 99.1 and is incorporated herein by reference.

The Registrant’s updated corporate presentation as of September 20, 2021, which has been posted to the Registrant’s website, is filed as Exhibit 99.2 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) | Exhibits.
| 99.1 |  | Dr. Jeffrey Miller Presentation as of September 17, 2021.
| 99.2 |  | GT Biopharma, Inc. Corporate Presentation as of September 20, 2021.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| GT BIOPHARMA, INC. |
Date: September 23, 2021 | By: | /s/ Michael Handelman |
|  | Michael Handelman |
|  | Chief Financial Officer |

3